Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL130129 | 0.89 | ACHE (0.50) | CASRMEN1KMT2ALMNACYP3A4 | |
| SCHEMBL128071 | 0.89 | ACHE (0.57) | MEN1KMT2ALMNACYP2D6ACHE | |
| Hydrochloric Acid SCHEMBL126742 | 0.87 | ACHE (0.56) | MEN1KMT2ALMNACYP2D6ACHE | |
| SCHEMBL132498 | 0.81 | ALDH1A1 (0.60) | CASRLMNAACHEALDH1A1SMN1; SMN2 | |
| SCHEMBL130443 | 0.80 | SMN1; SMN2 (0.60) | CASRLMNACYP3A4ALDH1A1SMN1; SMN2 | |
| SCHEMBL170262 | 0.77 | LMNA (0.46) | LMNACYP1A2CYP3A4CYP2D6ACHE | |
| SCHEMBL126714 | 0.76 | ALDH1A1 (0.55) | CASRLMNAACHEALDH1A1SMN1; SMN2 | |
| SCHEMBL126448 | 0.75 | CYP1A2 (0.46) | CASRLMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6158955 | 0.75 | EPHX2 (0.51) | LMNASMN1; SMN2 | |
| SCHEMBL125814 | 0.75 | SIGMAR1 (0.59) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283255-A1 | UREA DERIVATIVES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR | GALAPAGOS SASU (FR) | 2012-11-08 | — | — | US | disclosed |
| US-20120283255-A1 | UREA DERIVATIVES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR | GALAPAGOS SASU (FR) | 2012-11-08 | — | — | US | disclosed |
| US-8247412-B2 | Urea derivatives methods for their manufacture and uses thereof | GALAPAGOS SASU (FR) | 2012-08-21 | — | — | US | disclosed |
| US-8247412-B2 | Urea derivatives methods for their manufacture and uses thereof | GALAPAGOS SASU (FR) | 2012-08-21 | — | — | US | disclosed |
| US-8247412-B2 | Urea derivatives methods for their manufacture and uses thereof | GALAPAGOS SASU (FR) | 2012-08-21 | — | — | US | disclosed |
| EP-1874765-B1 | UREA DERIVATIVES, METHODS FOR THEIR MANUFACTURE AND USES THEREOF | GALAPAGOS SAS (FR) | 2012-03-07 | — | — | EP | disclosed |
| EP-2354137-A1 | Urea derivatives, methods for their manufacture, and uses thereof | Galapagos SAS (FR) | 2011-08-10 | — | — | EP | disclosed |
| US-20100240889-A1 | Urea Derivatives Methods For Their Manufacture And Uses Thereof | PROSKELIA SAS (FR) | 2010-09-23 | — | — | US | disclosed |
| US-20100240889-A1 | Urea Derivatives Methods For Their Manufacture And Uses Thereof | PROSKELIA SAS (FR) | 2010-09-23 | — | — | US | disclosed |
| US-20100240889-A1 | Urea Derivatives Methods For Their Manufacture And Uses Thereof | PROSKELIA SAS (FR) | 2010-09-23 | — | — | US | disclosed |
| EP-1874765-A2 | UREA DERIVATIVES METHODS FOR THEIR MANUFACTURE AND USES THEREOF | Proskelia SAS (FR) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006117211-A2 | UREA DERIVATIVES METHODS FOR THEIR MANUFACTURE AND USES THEREOF | PROSKELIA SAS (FR) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283255-A1 | UREA DERIVATIVES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR | UTS2R, UGP2, SLC14A1 | CASR 4125/4885MEN1 953/4885KMT2A 2979/4885 |
| US-20100240889-A1 | Urea Derivatives Methods For Their Manufacture And Uses Thereof | UGP2, UTS2R, UMPS | CASR 4045/4885MEN1 1697/4885KMT2A 2648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.